Ketorolaco Kabi (Ketorolac Trometamol)

Ketorolac trometamol blocks both COX‑1 and COX‑2 enzymes, reducing the production of prostaglandins that mediate inflammation and pain. This inhibition leads to decreased sensitization of pain receptors and provides fast analgesic effects.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s condition, weight, and renal function. Ketorolaco Kabi is administered by a healthcare professional via intramuscular or intravenous injection.

Safety data for ketorolac in pregnancy and lactation are limited. It is generally avoided in the third trimester and during breastfeeding unless the benefits outweigh potential risks, as advised by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Ketorolaco Kabi offers potent analgesia comparable to stronger opioids for short‑term use, but it carries a higher risk of renal and gastrointestinal adverse effects than less potent NSAIDs. It is typically reserved for situations where rapid, strong pain relief is essential and the treatment duration is limited.

Ketorolaco Kabi should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is supplied as a sterile solution for injection. It can be given intramuscularly or intravenously by a qualified healthcare professional, following aseptic technique and the dosage prescribed by the treating physician.

Serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe allergic reactions such as anaphylaxis, and increased cardiovascular events. Patients should be monitored closely for signs of these complications, especially when used with other high‑risk medications.

Ketorolaco Kabi is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active gastrointestinal bleeding, severe renal impairment, and those at high risk for cardiovascular events. It should also be avoided in patients who have had recent coronary artery bypass graft surgery.